Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the directors and management of Olo Inc. in relation to its acquisition by Thoma Bravo for $10.25 per share [1]. Group 1 - The investigation by the Schall Law Firm focuses on whether the Olo board acted in the best interests of its shareholders during the acquisition process [1]. - Olo Inc. has agreed to be acquired by Thoma Bravo at a price of $10.25 per share [1].

LOS ANGELES, Aug. 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or "the Company") (NASDAQ: PRAX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Praxis announced its Q2 2025 financial results on August 4, 2025. ...

Core Viewpoint - Novo Nordisk terminated its collaboration with Hims & Hers due to concerns over sales practices and "deceptive" marketing of the weight-loss drug Wegovy® [1][5]. Group 1: Company Actions and Legal Implications - Novo Nordisk's termination of the partnership with Hims & Hers occurred less than two months after the collaboration began, highlighting serious regulatory compliance issues [5]. - Following Novo Nordisk's announcement, securities class action lawsuits were filed against Hims & Hers and its executives, representing investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025 [2][6]. - Legal claims allege that Hims & Hers misled investors regarding its regulatory compliance and the revenue potential from its GLP-1 drug offerings [6][7]. Group 2: Regulatory Concerns and Market Impact - A group of over 80 bipartisan lawmakers urged the FDA to address the rising market for counterfeit GLP-1 drugs, citing risks to patient safety [4]. - The lawmakers' concerns were amplified by the fallout from the Hims & Hers and Novo Nordisk collaboration, which was marred by allegations of illegal compounding and deceptive marketing practices [4][5]. - Hims & Hers is accused of promoting unauthorized versions of Wegovy®, which could jeopardize patient safety and the company's relationship with Novo Nordisk [7][8].

SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- On July 25, 2025, investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares significantly fall during intraday trading on reports that U.S. lawmakers urged the FDA to act against copycat versions of weight loss drugs, citing safety concerns. This latest development follows an announcement by Novo Nordisk on June 23, 2025, the Danish maker of the FDA-approved weight-loss medication Wegovy® (a GLP-1 treatment for obesity), that it termina ...

Core Viewpoint - Hims & Hers Health, Inc. is facing securities class action lawsuits due to allegations of misleading investors regarding its GLP-1 drug offerings and deceptive marketing practices, particularly in relation to its collaboration with Novo Nordisk [1][7][9]. Group 1: Legal Actions and Investigations - Securities class action lawsuits were filed against Hims & Hers and certain executives, representing investors who acquired securities between April 29, 2025, and June 23, 2025 [1][3]. - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [3][11]. - The lead plaintiff deadline for the lawsuits is set for August 25, 2025 [3]. Group 2: Events Leading to Lawsuits - Hims & Hers began offering GLP-1 treatments in May 2024, initially through compounded semaglutide, and later with FDA-approved injectable semaglutide [4]. - The FDA resolved a semaglutide product shortage on February 21, 2025, which limited Hims & Hers' ability to sell compounded semaglutide [5]. - Following assurances from management about regulatory compliance during a Q4 earnings call, Hims & Hers announced a collaboration with Novo Nordisk on April 29, 2025, which initially boosted share prices [6]. Group 3: Allegations and Marketing Practices - The lawsuits allege that Hims & Hers provided misleading assurances about its regulatory compliance and revenue from GLP-1 offerings, failing to disclose critical business practices [7]. - Plaintiffs claim that Hims & Hers engaged in deceptive marketing of unauthorized versions of Wegovy®, exposing patients to unknown risks [8]. - Novo Nordisk terminated its collaboration with Hims & Hers on June 23, 2025, citing violations of U.S. regulations regarding the sale of compounded drugs [9][10]. Group 4: Market Impact - The announcement of Novo Nordisk's termination of the partnership led to a 30% drop in Hims & Hers' share price [10].

Core Viewpoint - The Schall Law Firm is investigating Gilead Sciences, Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding its HIV treatment trials [1][2]. Group 1: Investigation Details - The investigation centers on whether Gilead issued false or misleading statements or failed to disclose critical information to investors [2]. - On June 10, 2025, Gilead announced that the U.S. FDA placed a clinical hold on its HIV treatment trials for GS-1720 and GS-4182 due to safety concerns, specifically a decrease in CD4+ T-cell and absolute lymphocyte counts in some trial participants [2]. Group 2: Legal Representation - The Schall Law Firm offers free consultations for shareholders who may have suffered losses and encourages them to reach out for assistance [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Core Viewpoint - The Schall Law Firm is investigating Harrow, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Financial Performance - Harrow, Inc. reported Q1 2025 financial results on May 8, 2025, with revenues that fell short of consensus estimates and an adjusted EBITDA of -$1.9 million [2]. - Following the announcement of these results, Harrow's shares experienced a decline of over 4% [2].

Core Viewpoint - ClaimsFiler informs investors about the deadline to file lead plaintiff applications in securities class action lawsuits against Organon & Co. for the Class Period from October 31, 2024, to April 30, 2025 [1] Group 1: Lawsuit Details - Organon and certain executives are accused of failing to disclose material information during the Class Period, violating federal securities laws [3] - The first-filed case is Hauser v. Organon & Co., et al., and a subsequent case, Lerner v. Organon & Co., et al., expanded the class period [5] Group 2: Financial Impact - On March 10, 2025, Organon announced a significant reduction in its dividend payout from $0.28 to $0.02, which contradicted previous assurances to investors [4] - Following the dividend announcement, Organon's share price dropped over 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4] Group 3: Investor Support - ClaimsFiler provides resources for investors to recover funds from securities class action settlements, including free registration for information access and case evaluations [6]

Core Viewpoint - The Schall Law Firm is investigating Neogen Corporation for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Neogen issued false or misleading statements and failed to disclose critical information to investors [2]. - On June 4, 2025, Neogen acknowledged that its Q4 2025 financial results would be "materially approximate" to previous guidance but expected an EBITDA margin in the "high-teens," a significant decline from the prior quarter's margin of 22% [2]. - The company attributed this decline to "elevated inventory write-offs," which led to a 17.3% drop in Neogen's share price on the same day [2].

Core Viewpoint - The Schall Law Firm is investigating ADTRAN Holdings, Inc. for potential violations of securities laws related to misleading financial statements and disclosures [1][2]. Group 1: Investigation Details - The investigation centers on whether ADTRAN issued false or misleading statements and failed to disclose critical information to investors [2]. - ADTRAN's Audit Committee concluded that the financial results for the non-controlling interest and net loss were materially misstated in several quarterly reports for the periods ending March 31, 2023, June 30, 2023, and September 30, 2023 [2]. Group 2: Financial Reporting Issues - The financial statements from the Non-Reliance Periods should no longer be relied upon due to the identified misstatements [2].